Pietrantonio F, et al. - Researchers conducted this single-center phase II study for analyzing the activity of perioperative capecitabine, oxaliplatin, irinotecan, and bevacizumab (COI-B regimen) in patients with potentially resectable colorectal cancer liver metastases (CRCLM) and examining biomarkers for early pathologic response prediction. Study participants included patients with liver-limited, borderline resectable disease and/or high-risk features. In patients with molecularly unselected, potentially resectable CRCLM, the COI-B regimen is a feasible and highly active perioperative strategy. Findings suggested a significant association of early tumor shrinkage [ETS] and lower standardized uptake volume [SUV]-2 with pathologic response. Diarrhea and neutropenia in the preoperative phase and thromboembolic events in the postoperative phase were the most frequent grade 3/4 adverse events.